Why the study?
Do plasma angiogenic biomarkers (VEGF-A, Ang1, Ang2) predict the severity of liver failure and complications in patients with alcoholic liver disease?
Do plasma angiogenic biomarkers (VEGF-A, Ang1, Ang2) predict the severity of liver failure and complications in patients with alcoholic liver disease?
Plasma Ang2 levels may serve as a useful noninvasive biomarker for predicting severe liver dysfunction and complications in patients with alcoholic liver disease.
Answers are grounded in this paper and cite their sources.
May support noninvasive monitoring in alcoholic liver disease; hypothesis-generating and requires prospective validation before clinical use.
Angiogenesis is believed to be implicated in the pathogenesis of alcoholic liver disease (ALD). We aimed to explore the usefulness and accuracy of plasma angiogenic biomarkers for noninvasive evaluation of the severity of liver failure and ALD outcome. One hundred and forty-seven patients with ALD were prospectively enrolled and assessed based on their (1) gender, (2) age, (3) severity of liver dysfunction according to the Child-Turcotte-Pugh and MELD scores, and (4) the presence of ALD complications. Plasma levels of vascular endothelial growth factor (VEGF-A) and angiopoietins 1 and 2 (Ang1 and Ang2) were investigated using ELISAs. Multivariable logistic regression was applied in order to select independent predictors of advanced liver dysfunction and the disease complications. Significantly higher concentrations of Ang2 and VEGF-A in ALD patients as compared to controls were found. There was no difference in Ang1 levels in both groups. A positive correlation of Ang2 levels with INR (Rho 0.66; P < 0.0001) and its inverse correlation with plasma albumin levels (Rho -0.62; P < 0.0001) were found. High Ang2 concentrations turned out to be an independent predictor of severe liver dysfunction, as well as hepatic encephalopathy and renal impairment. Ang2 possessed the highest diagnostic and prognostic potential among three studied angiogenesis-related molecules.
No takes yet. Share an insight, caveat, or question.
Kasztelan‐Szczerbińska et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: